Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?

Nawel Jaafar, Francesca Girolami, Ihsen Zairi, Sondes Kraiem, Mohammed Hammami, Iacopo Olivotto

Abstract


We recently performed next generation sequencing (NGS) genetic screening in 11 consecutive and unrelated Tunisian HCM probands seen at Habib Thameur Hospital in Tunis in the first 6 months of 2014, as part of a cooperative study between our Institutions. The clinical diagnosis of HCM was made according to standard criteria. Using the Illumina platform, a panel of 12 genes was analyzed including myosin binding protein C (MYBPC3), beta-myosin heavy chain (MYH7), regulatory and essential light chains (MYL2 and MYL3), troponin-T (TNNT2), troponin-I (TNNI3), troponin-C (TNNC1), alpha-tropomyosin (TPM1), alpha-actin (ACTC1), alpha-actinin-2 (ACTN2) as well as alfa-galactosidase (GLA), 5′-AMP-activated protein (PKRAG2), transthyretin (TTR) and lysosomal-associated membrane protein-2 (LAMP2) for exclusion of phenocopies. Our preliminary data, despite limitations inherent to the small sample size, suggest that HCM in Tunisia may have a peculiar genetic background which privileges rare genes overs the classic HCM-associated MHY7 and MYBPC3 genes.

Full Text:

PDF

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Nawel Jaafar, Francesca Girolami, Ihsen Zairi, Sondes Kraiem, Mohammed Hammami, Iacopo Olivotto

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.